8-K: Ensysce Biosciences Secures $4M Financing, Accelerates Pain Programs

Ensysce Biosciences has closed a $4 million convertible preferred stock financing, with potential for an additional $16 million, to advance its pain management programs.

Summary

• Ensysce Biosciences, Inc. (ENSC) entered into a Securities Purchase Agreement on November 13, 2025, with an institutional investor for a $4 million financing.
• The financing includes a Registered Direct Offering of 1,513 shares of Series B Preferred Stock (convertible into 665,922 Common Stock shares) for approximately $1.7 million.
• A concurrent Private Placement involved the sale of 2,487 unregistered shares of Series B Preferred Stock (convertible into 1,094,078 Common Stock shares) and warrants to purchase up to 880,000 Common Stock shares.
• The total initial gross proceeds from the offerings are $4 million, with an estimated $3.6 million in net proceeds.
• The Series B Preferred Stock has an initial stated value of $1,100 per share and pays a dividend at an annual rate of 4%, increasing to 8% upon certain 'Triggering Events'.
• The conversion price for the Preferred Stock and the exercise price for the Warrants is $2.50 per share of Common Stock, subject to adjustment.
• The company is restricted from issuing Common Stock or equivalents that would exceed 19.99% of outstanding Common Stock without stockholder approval (Exchange Cap).
• Ensysce is obligated to file a resale registration statement for the securities issued in the Private Placement and will seek stockholder approval for the Exchange Cap.
• The net proceeds will be used for general corporate purposes, including the continued development of its TAAP and MPAR programs and for working capital.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. The company successfully secured crucial funding for its clinical programs and has access to additional capital. This is a significant step forward for a clinical-stage biotech. However, the financing involves substantial potential dilution for existing shareholders and complex terms, which temper the overall positive outlook.

Positives

• Secured $4 million in immediate financing, providing crucial capital for operations.
• Potential for up to an additional $16 million in funding through future tranches over the next 24 months, offering financial flexibility.
• The funding will accelerate the Phase 3 clinical program for PF614, Ensysce's flagship analgesic candidate, aiming for completion within 18-24 months.
• Management highlights 'strong investor confidence' in the company's vision for safe and effective pain management.
• The company's MPAR program is also supported by federal grants, indicating external validation and diversified funding sources.

Negatives

• The issuance of convertible preferred stock and warrants introduces significant potential dilution to existing common stockholders.
• The company is restricted from certain future financing structures (Variable Rate Transactions) without investor consent if the investor holds a minimum shareholding.
• Failure to obtain stockholder approval for the Exchange Cap could limit the conversion of preferred shares and exercise of warrants, potentially requiring cash redemption by the company.
• The company is obligated to hold special shareholder meetings every four months to seek stockholder approval if not obtained at the first meeting, incurring ongoing costs and effort.

Risks

• The issuance of the Securities may result in substantial dilution of the outstanding shares of Common Stock under certain market conditions.
• Product candidates are in clinical stages and not yet approved; there is no assurance of successful clinical development, regulatory approval, or commercialization.
• Potential for problems or delays in clinical development could impact timelines and costs.
• The company's ability to fund its continued operations, including planned clinical trials, is a risk, despite the current financing.
• The dilutive effect of stock issuances from fundraising could negatively impact existing stockholders' equity interests.
• The company's and its partners' ability to perform under license, collaboration, and manufacturing arrangements is crucial for program success.
• Triggering Events (e.g., failure to file/effect registration statement timely, lapse of registration effectiveness, trading suspension, insufficient authorized shares, failure to pay amounts due, default on $500,000+ indebtedness, bankruptcy, material adverse effect, common stock price below Floor Price) could lead to increased dividend rates or alternate conversion rights for holders.

Future Outlook

The company intends to use the net proceeds to accelerate the Phase 3 clinical program for PF614, aiming for completion within the next 18-24 months. It also plans to continue innovation in abuseand overdose-resistant analgesics through its TAAP and MPAR platforms, moving closer to delivering transformative treatments.

Management Comments

• "This financing demonstrates strong investor confidence in Ensysces vision: safe, effective analgesics that re-invent pain management."
• "With PF614 on track for Phase 3 completion in the next 18 months and federal grant support for our MPAR program, we are moving closer to delivering transformative treatments for patients in urgent need."

Industry Context

This financing positions Ensysce Biosciences, a clinical-stage biotech company, to advance its novel opioid candidates (PF614, TAAP, MPAR programs) in the pain management sector. The focus on abuseand overdose-resistant analgesics addresses a critical public health need and regulatory priority, potentially differentiating its products in a highly scrutinized market. The funding supports progression through costly clinical trial phases, a common challenge for companies in this industry.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Face significant potential dilution from the conversion of Series B Preferred Stock and exercise of Warrants. Their voting power may be affected by the need for stockholder approval for certain issuances and the protective voting rights granted to preferred holders.
• **Investors (Purchaser)**: Gained a senior position in the capital structure with preferential dividend and liquidation rights, strong anti-dilution protections, and warrants, providing a potentially attractive risk-adjusted return.
• **Company**: Secured critical capital to fund ongoing operations and accelerate key clinical development programs, which is vital for its long-term strategic objectives and product pipeline progression.
• **Employees**: Continued development of programs may provide job security and potential for growth, contingent on clinical success and further funding.

Next Steps

• File a resale registration statement for the securities issued in the Private Placement within fifteen days after the closing date.
• Hold a special meeting of stockholders within 60 days of the Initial Closing Date to obtain Stockholder Approval for the Exchange Cap.
• If Stockholder Approval is not obtained at the first meeting, call a meeting every four months thereafter until approval is secured or warrants are no longer outstanding.
• Continue the Phase 3 clinical program for PF614, aiming for completion within 18-24 months.
• Maintain a reserve of 200% of the required minimum Common Stock for issuance pursuant to the Transaction Documents.

Key Dates

Recommendation

The financing provides essential capital for Ensysce Biosciences to advance its critical clinical programs, which is a positive development for a biotech company. However, the terms involve substantial potential dilution for existing common shareholders and introduce complex capital structure considerations, including the need for ongoing stockholder approvals and protective provisions for the new preferred investors. Given the inherent risks in clinical-stage drug development and the dilutive nature of the financing, a 'hold' recommendation is appropriate. Investors should monitor the progress of clinical trials and the company's ability to manage its capital structure and dilution effectively.

Keywords

Biotech, Pharmaceuticals, Pain Management, Opioids, Abuse Deterrent, Overdose Protection, Convertible Preferred Stock, Warrants, Capital Raise, SEC Filing, ENSC, Ensysce Biosciences, Clinical Trials, Phase 3, TAAP, MPAR, Dilution